Intervention

Glibenclamide

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting0

Common conditions10

Lead sponsors shown10

Clinical trials

10 shown

Low dosE GlibENclamide in Diabetes Part ANCT02830048 · 2016-07-01

Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP ChannelsNCT02375828 · 2015-03-20

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)NCT02318693 · 2015-02-04

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over StudyNCT02201602 · 2014-08-01

A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteSNCT02080377 · 2014-07-01

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and HypertensionNCT02145611 · 2013-07-01

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 DiabetesNCT01822548 · 2010-10-01

Risk of Hypoglycemia in Type 2 DiabetesNCT00734669 · 2008-07-01

Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?NCT00472875 · 2007-05-01

GALLANT 4 Tesaglitazar vs. GlibenclamideNCT00255541 · 2004-09-01

Common conditions

Type 2 Diabetes3 Type 2 Diabetes Mellitus2 Diabetes1 Diabetes Mellitus, Type 21 Endothelial Dysfunction1 Gestational Diabetes1 Hypertension1 Neonatal Diabetes Secondary to Mutation in the Potassium Channel1 Pregnancy1 Type 1 Diabetes Mellitus1

Leading sponsors

Assistance Publique - Hôpitaux de Paris1 AstraZeneca1 Azienda Ospedaliero-Universitaria di Parma1 Dr. José Fernando Vilela-Martin MD PhD1 Khoo Teck Puat Hospital1 King's College Hospital NHS Trust1 Merck Sharp & Dohme LLC1 University of Edinburgh1 University of Giessen1 University of Oxford1

Trial status mix

COMPLETED8

TERMINATED1

UNKNOWN1

Phase mix

PHASE34

PHASE44

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.